Results 11 to 20 of about 3,046 (215)

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. [PDF]

New England Journal of Medicine
BACKGROUND Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain.
Milind Y. Desai, A. Owens, T. Abraham, I. Olivotto, P. García-Pavía, Renato D. Lopes, P. Elliott, Fábio Fernandes, N. Verheyen, Lars Maier, B. Meder, O. Azevedo, H. Kitaoka, K. Wolski, Qiu-Qing Wang, Wael Jaber, Lisa Mitchell, Jonathan Myers, Thomas Rano, Zhiqun Gong, Y. Zhong, Suzanne Carter-Bonanza, V. Florea, Ron Aronson, Steve E. Nissen   +24 more
semanticscholar   +8 more sources

Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study

Cardiology and Therapy
Introduction Mavacamten, a cardiac myosin inhibitor, has demonstrated positive outcomes in left ventricular outflow tract (LVOT) gradient reduction and improvements of symptoms and function in Chinese patients with symptomatic obstructive hypertrophic ...
Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’an Wang, Yunqi Shi, Daoquan Peng, Ping Yang, Wei Ma, Fang Wang, Wei Jin, Xiang Cheng, Yu-Mao Chen, Yue Zhong, Yu Chen Barrett, Jing Zheng, Shuyang Zhang   +16 more
doaj   +3 more sources

Paradoxical Rise in Pulmonary Artery Pressure Following Successful Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy: A Case Report [PDF]

Clinical Case Reports
A paradoxical rise in pulmonary artery pressure on follow‐up echocardiography after successful mavacamten therapy for obstructive hypertrophic cardiomyopathy (oHCM) prompted right heart catheterization, which demonstrated combined pre‐ and post‐capillary
Mengdian Zhang
doaj   +3 more sources

Heart failure reporting signals associated with concomitant mavacamten and CYP inhibitors in obstructive hypertrophic cardiomyopathy: a real-world pharmacovigilance study with propensity score matching [PDF]

Frontiers in Pharmacology
BackgroundMavacamten, a cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (HOCM), carries a risk of excessive negative inotropy.
Daqiu Chen, Yanqing Wu, Zhanxiong Xie, Wenchao Qiu, Xiaomai Huang, Shanghua Xu, Shunxiang Luo   +6 more
doaj   +3 more sources

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ahmad Masri, Miriam R Elman, Hongya Chen
exaly   +4 more sources

Mavacamten

JACC: Advances
[Figure: see text]
Matthew W. Martinez, MD, Dewey Seto, BSBA, Michael Cheung, DHSc, Michele Coiro, MBA, Niki Patel, PharmD, Arnaud Bastien, MD, Jeffrey Lockman, PhD, Sonia Afsari, MD, Milind Y. Desai, MD, MBA   +8 more
doaj   +12 more sources

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy

Biomedicines
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Helin Savsin, Tomasz Tokarek
doaj   +4 more sources

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population

Journal of the American Heart Association
Background Patients with obstructive hypertrophic cardiomyopathy have increased symptomatic burden. Mavacamten was recently approved for treatment of obstructive hypertrophic cardiomyopathy based on 2 randomized controlled trials.
Richard T Carrick, Victoria Blake, Lili A Barouch   +2 more
exaly   +4 more sources

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy.
Anjali T. Owens, Milind Desai, Matthew T. Wheeler, Anna Rodonski, Samira Merali, Amy J. Sehnert, Sara Saberi   +6 more
doaj   +3 more sources

Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction

Nature Communications
Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by β-cardiac myosin ...
Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W. Schmidt, Hans-Joachim Knölker, Anne Houdusse   +8 more
doaj   +3 more sources